9.50Open9.50Pre Close0 Volume7 Open Interest10.00Strike Price0.00Turnover0.00%IV12.72%PremiumOct 18, 2024Expiry Date7.30Intrinsic Value100Multiplier-2DDays to Expiry2.20Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2.18Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Boxman : Dr. Bart Van Putte, Cardiothoracic Surgeon at St. Antonius Hospital, used the Company’s Cardiac Surgery System to successfully treat two patients with atrial fibrillation at St. Antonius Hospital, Nieuwegein, The Netherlands. Dr. Van Putte was joined by colleagues and Pulse Biosciences’ Chief Medical Officer, Cardiac Surgery, Dr. Gan Dunnington and Chief Science Officer, Cardiac Surgery, Dr. Niv Ad during the concomitant procedure. The first-in-human feasibility study is a multicenter study of up to 30 patients that will include an endocardial catheter-based remapping to confirm chronic isolation at approximately three months post treatment